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common practice and most patients un-
dergo plasma exchange despite the activity 
of ADAMTS-13 being commonly normal. 
In consequence, this approach has an un-
satisfying response rate between 20 and 
50%.
Eculizumab is a humanized monoclo-
nal antibody blocking complement activa-
tion. It is directed against C5 [6]. The major 
indication for eculizumab is paroxysmal 
nocturnal hemoglobinuria (PNH). How-
ever, it has been used with success in atypi-
cal hemolytic uremic syndrome (HUS), 
even after alloSCT [7, 8]. Eculizumab has 
been recommended as a lifelong therapy 
since PNH clones will not be eliminated 
and genetic alterations leading to atypical 
HUS persist. Since eculizumab inhibits the 
complement pathway, this therapy can be 
associated with severe infections as side ef-
fects [6, 9]. The approach to withdraw ecu-
lizumab after successful therapy of atypical 
HUS is under discussion [10–12]. There-
fore, it would be desirable and could be 
possible to limit the administration of ec-
ulizumab in nongenetically determined 
TMA, especially in highly immunosup-
pressed patients after alloSCT with or with-
out GvHD.
Calcineurin inhibitor (CNI)-associated 
thrombotic microangiopathy (TMA) is a 
severe and often fatal complication after 
allogeneic stem cell transplantation (allo-
SCT) [1–3]. Administration of the CNIs 
cyclosporine-A and tacrolimus as well as 
sirolimus has been described as a risk fac-
tor [4]. Thrombocytopenia, the occur-
rence of schistocytes, and progredient ane-
mia in conjunction with an increase in lac-
tate dehydrogenase in the absence of anti-
erythrocyte antibodies leads to diagnosis. 
Progredient renal failure and involvement 
of the CNS as described for TTP may oc-
cur. Diagnosis may be difficult since a va-
riety of other problems may cause the ad-
dressed symptoms (except the occurrence 
of schistocytes): cytopenia may be caused 
by infections or related to graft-versus-
host disease (GvHD), and drugs like cyclo-
sporine-A can induce an increase in cre-
atinine. Treatment of TMA is difficult and 
a therapeutic standard for therapy of CNI-
associated TMA has not been established 
so far [5]. The discontinuation of CNIs is 
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We here report our experience with dis-
continuation of eculizumab for transplant-
associated TMA in 2 patients. In both pa-
tients, ADAMTS-13 deficiency was exclud-
ed prior to eculizumab therapy. Further-
more, a molecular analysis of the genes 
CFH, CFI, C3, CFB, ADAMTS-13, CFHR1, 
and CLU revealed no evidence for geneti-
cally determined HUS, either in samples 
from recipients or from stem cell donors.
Patient 1 was a 36-year-old CMV+ male 
suffering from a lymphocytic lymphoma 
carrying a p53 deletion. A partial remission 
could be induced by treatment with ib- 
rutinib. He was conditioned myeloabla-
tively with busulfan16 mg/kg/cyclophospha-
mide120 mg/kg and low-dose alemtuzumab 
and allografted with nonmanipulated pe-
ripheral stem cells (8.48 × 106 CD34+ cells/
kg) from a CMV+ male donor. Cyclospo-
rine-A and short-course methotrexate 
were given for GvHD prophylaxis. Throm-
bocytes engrafted on day +8 and leucocytes 
on day +11. Ibrutinib was given for lym-
phoma relapse and GvHD prophylaxis was 
stopped to enhance graft-versus-leukemia 
effects. Cutaneous GvHD stage 3 (2° over-
all) was treated with cyclosporine-A and 
methylprednisolone. The lymphoma re-
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gressed into a continuous complete remis-
sion. The patient developed hemolytic ane-
mia in conjunction with renal failure, a de-
crease in platelets, and the occurrence of 
schistocytes of maximal 38/1,000 (Table 1). 
ADAMTS-13 activity was normal. CNI was 
discontinued and treatment of GvHD was 
switched to methylprednisolone in con-
junction with mycophenolate. Five ses-
sions of plasmapheresis did not improve 
any parameter of TMA and treatment with 
eculizumab was initiated. Therapy with ec-
ulizumab and prophylaxis of infections 
were performed according the manufac-
turer’s instructions. A total of 16 infusions 
were given over 6 months. Parameters of 
TMA normalized rapidly (Table 1; Fig. 1). 
In addition, common anti-infectious pro-
phylaxes after alloSCT were given. Steroid-
induced myopathy occurred, methylpred-
nisolone was discontinued, and ruxolitinib 
(2 × 5–10 mg) was initiated for therapy of 
chronic GvHD (extensive disease) [13]. Re-
peated episodes of CMV and HHV6 reac-
tivations were treated virustatically. Due to 
the high infection rate, eculizumab was dis-
continued after 6 months and controls of 
Table 1. Characteristics, therapy, and course of thrombotic microangiopathy (TMA)
Parameter Patient 1 Patient 2
Age at alloSCT, gender 36 years, male 59 years, female
Diagnosis Small cell lymphocytic lymphoma, 
17p-deletion
Multiple myeloma IgGκ, del17p + other  
aberrations
Conditioning Busulfan/cyclophosphamide/  
alemtuzumab
Melphalan, fludarabine, ATG
Donor type, HLA match Matched-unrelated (10/10) Matched-related (sister) (10/10)
Active GvHD at onset of TMA Acute GvHD, skin 3° (2° overall) Chronic GvHD, extensive disease, skin, lung
Interval alloSCT > TMA 37 days 18 months
Parameters at diagnosis of TMA
Hemoglobin 4.3 mmol/L 5.4 mmol/L
Reticulocytes 5.94% 9.38%
Platelet count 13/nL 32/nL
Schistocytes at onset/maximum 38/1,000 (at onset = maximum) 17/1,000 erythrocytes (at onset = maximum)
LDH 13.9 µkat/L 12.2 µkat/L
Haptoglobin n.d. <0.08 g/L
Bilirubin 57.3 µmol/L 25.7 µmol/L
Serum creatinine/clearance 145 µmol/L 53 µmol/L
CNS involvement No Yes
Primary therapy of TMA
Plasmapheresis 5 sessions over 6 days 5 sessions over 5 days
Result No response Minor response
Salvage therapy of TMA
Start 6 days after onset of TMA 8 days after onset of TMA
Modality Eculizumab, 16 infusions Eculizumab, 7 infusions
Stop 6 months after onset of TMA 2 months after onset of TMA
Improvement of symptoms and laboratory parameters (days after start of eculizumab)
Decrease in schistocytes After 1 day After 1 day
Increase in platelets 3 days 2 days
Decrease in LDH 6 days Not evaluable
Clinical improvement n.a. Within a few days (CNS)
Parameters at last laboratory follow-up
Interval from eculizumab discontinuation 13 weeks 18 weeks
Schistocytes 0 0 (8.5 months after eculizumab  
discontinuation)
Reticulocytes 1.23% 0.88%
Haptoglobin 1.4 g/L 1.6 g/L
Normal values: hemoglobin: 7.4 – 10 mmol/L (female), 8.6 – 11.2 mmol/L (male); thrombocytes: 140 – 440/nL; reticulocytes: 0.5 – 
2.6%; schistocytes: <5/1,000 erythrocytes; LDH (lactate dehydrogenase): 0 – 4.22 µkat/L; bilirubin: 0 – 17 µmol/L; haptoglobin: 0.3 – 2.0 
g/L; creatinine: 42 – 80 µmol/L (female), 49 – 97 µmol/L (male). n.d., not done; n.a., not applicable.
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TMA parameters gave no hint for relapse 
of atypical HUS after a further follow-up of 
2.5 months (Table  1). Chronic GvHD is 
currently excellently controlled by ruxoli-
tinib 2 × 10 mg. The patient has a Karnof-
sky score of 80%, and has no signs of active 
GvHD, infectious complications, or TMA 
4.5 months after the discontinuation of ec-
ulizumab. 
Patient 2 was a 59-year-old female, who 
was allografted from her HLA-identical 
sister for myeloma relapse after high-dose 
melphalan and autologous SCT. She was 
transferred from a local hospital to our unit 
18 months after alloSCT with thrombocy-
topenia, progredient anemia, headache, 
and anisocoria, highly suggestive for TMA. 
Furthermore, she suffered from extensive 
chronic GvHD with cutaneous, mucosal, 
hepatic, and pulmonary manifestation. 
CNS infection or bleeding were excluded 
by CT scan and peripheral blood smear 
showed 17/1,000 schistocytes. LDH, biliru-
bin, and reticulocytes were increased, and 
haptoglobin was reduced. The kidneys 
were not involved (Table 1; Fig. 1). Tacro-
limus had been terminated by telephonic 
advice prior to admission. Initial treat-
ments of TMA were 5 sessions of plasma-
pheresis. Since plasmapheresis led only to 
minor improvement of CNS symptoms 
and ADAMTS-13 level was normal, the 
treatment was switched to eculizumab. 
Therapy with eculizumab and prophylaxis 
of infections were performed according the 
manufacturer’s instructions. A total of 7 in-
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Fig. 1. Course of schistocytes (fragmentocytes)/1,000 red cells. a Patient 1. b Patient 2. The vertical lines indicate 
the months and the broken horizontal line the upper normal value. The arrows indicate the beginning and end 
of therapy with eculizumab. Patient 2: the second peak after the discontinuation of eculizumab is due to a period 
of hemodialysis.
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fusions were given over 2 months. Head-
ache and anisocoria disappeared rapidly 
and schistocytes and reticulocytes de-
creased. Further therapy of chronic GvHD 
was mycophenolate in combination with 
methylprednisolone and ruxolitinib (2 × 
5–10 mg) [13]. Severe pulmonary GvHD in 
conjunction with an abdominal compart-
ment syndrome after massive gastrointes-
tinal bleeding required artificial respiration 
and hemodialysis, leading to a transient in-
crease in schistocytes. Due to infectious 
problems, eculizumab was terminated after 
2 months. The patient was under weaning 
from artificial respiration with moderately 
controlled chronic GvHD under ruxoli-
tinib/mycophenolate/methylpredniso-
lone. She died from severe GvHD without 
clinical or laboratory signs of TMA 8.5 
months after onset (Table 1; Fig. 1).
The excellent response of atypical TMA 
after alloSCT to eculizumab in 2 of 2 pa-
tients as well as the association of TMA 
with other severe complications after al-
loSCT is in accordance with other reports. 
It has been not clarified so far whether 
atypical HUS after alloSCT requires life-
long therapy with eculizumab like patients 
suffering from PNH. In their series, de 
Fontbrune et al. [7] terminated eculizumab 
only in nonresponders or in the case of 
other severe problems such as refractory 
GvHD or relapsing malignancy. Termina-
tion of eculizumab would be desirable after 
alloSCT with or without GvHD, since it 
leads to additional immunosuppression by 
blocking complement activation. In both 
of the reported patients, eculizumab was 
terminated after exclusion of evidence for 
genetically determined HUS 6 and 2 
months after treatment began, respective-
ly, due to severe infections under monitor-
ing of parameters indicating active TMA. 
No patient developed relapse of TMA: one 
could be discharged with a Karnofsky score 
of 80%, and the other was under weaning 
from artificial respiration. The authors 
conclude cessation of eculizumab therapy 
in these patients should be attempted to 
avoid long-term complement block in 
highly immunosuppressed patients. Moni-
toring of TMA parameters is mandatory. 
Further follow-up and confirmation or re-
buttal of our results in additional patients 
with this rare complication after alloSCT is 
necessary.
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